The current pathological diagnosis of aldosterone-producing adenoma (APA) is challenging because no histological markers of aldosterone production are available in routine practice. A previous study demonstrated that Disabled-2 (DAB2) is a specific marker of the zona glomerulosa (ZG) in rodents. The aim of the present study was to investigate the significance of immunohistochemical staining to detect DAB2 in the adrenal tissue of patients with APA. We investigated the expression of DAB2 in 36 adrenal glands with APA, 23 adrenal glands with cortisol-producing adenoma (CPA), and 33 adrenal glands with non-functioning adenoma (NFA). Immunohistochemical staining was performed using anti-DAB2 antibodies on paraffin-embedded sections. We analysed the expression of DAB2 semi-quantitatively by scoring staining intensity, and assessed the correlation of this information with the clinical findings. DAB2 mRNA expression in adenoma tissues was evaluated by RT-PCR. DAB2 was highly expressed in the ZG in normal human adrenal glands. DAB2 expression was heterogeneous in APA, with spotted, strong staining noted in most samples (25 of 36 APA). CPA and NFA also exhibited extensive low or moderate DAB2 expression. DAB2 mRNA was significantly increased and positively correlated with CYP11B2 in APA (p<0.05). In APA, the DAB2 score adjusted for tumour volume was positively correlated with plasma aldosterone (p<0.05). Patients with low or moderate DAB2 staining more frequently exhibited high blood pressure and were diagnosed at a younger age compared with patients with high DAB2 staining. The present study clearly demonstrates that DAB2 is a specific marker of the ZG in normal human adrenal glands but that DAB2 immunostaining is not sufficiently powerful for histopathological diagnosis of APA. DAB2 might be involved in excessive aldosterone biosynthesis and correlate with specific clinical characteristics of APA patients.
* These authors contributed equally to this work
References
1
Rossi GP,
Bernini G,
Caliumi C,
Desideri G,
Fabris B,
Ferri C,
Ganzaroli C,
Giacchetti G,
Letizia C,
Maccario M,
Mallamaci F,
Mannelli M,
Mattarello MJ,
Moretti A,
Palumbo G,
Parenti G,
Porteri E,
Semplicini A,
Rizzoni D,
Rossi E,
Boscaro M,
Pessina AC,
Mantero F.
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300
2
Sang X,
Jiang Y,
Wang W,
Li Y,
Zhao J,
Peng Y,
Gu W,
Chen G,
Liu W,
Ning G.
Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens 2013; 31: 1465-1471
4
Funder JW,
Carey RM,
Fardella C,
Gomez-Sanchez CE,
Mantero F,
Stowasser M,
Young Jr. WF,
Montori VM.
Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281
5
Milliez P,
Girerd X,
Plouin PF,
Blacher J,
Safar ME,
Mourad JJ.
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248
6
Stowasser M,
Sharman J,
Leano R,
Gordon RD,
Ward G,
Cowley D,
Marwick TH.
Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005; 90: 5070-5076
9
Volpe C,
Höög A,
Ogishima T,
Mukai K,
Lu M,
Thorén M,
Hamberger B.
Immunohistochemistry improves histopathologic diagnosis in primary aldosteronism. J Clin Pathol 2013; 66: 351-354
11
Monticone S,
Castellano I,
Versace K,
Lucatello B,
Veglio F,
Gomez-Sanchez CE,
Williams TA,
Mulatero P.
Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Mol Cell Endocrinol 2015; 411: 146-154
12
Dekkers T,
ter Meer M,
Lenders JW,
Hermus AR,
Schultze Kool L,
Langenhuijsen JF,
Nishimoto K,
Ogishima T,
Mukai K,
Azizan EA,
Tops B,
Deinum J,
Küsters B.
Adrenal nodularity and somatic mutations in primary aldosteronism: one node is the culprit?. J Clin Endocrinol Metab 2014; 99: E1341-E1351
13
Xu XX,
Yang W,
Jackowski S,
Rock CO.
Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product. J Biol Chem 1995; 270: 14184-14191
14
Romero DG,
Yanes LL,
de Rodriguez AF,
Plonczynski MW,
Welsh BL,
Reckelhoff JF,
Gomez-Sanchez EP,
Gomez-Sanchez CE.
Disabled-2 is expressed in adrenal zona glomerulosa and is involved in aldosterone secretion. Endocrinology 2007; 148: 2644-2652
16
Gioco F,
Seccia TM,
Gomez-Sanchez EP,
Rossi GP,
Gomez-Sanchez CE.
Adrenal histopathology in primary aldosteronism: is it time for a change?. Hypertension 2015; 66: 724-730
18
Zhang Z,
Chen Y,
Tang JJ,
Xie X.
Frequent loss expression of dab2 and promotor hypermethylation in human cancers: A meta-analysis and systematic review. Pak J Med Sci 2014; 30: 432-437
21
Choi M,
Scholl UI,
Yue P,
Björklund P,
Zhao B,
Nelson-Williams C,
Ji W,
Cho Y,
Pate A,
Men CJ,
Lolis E,
Wisgerhof MV,
Geller DS,
Mane S,
Hellman P,
Westin G,
Åkerström G,
Wang W,
Carling T.
Lifton RP. K+ Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension. Science 2011; 331: 768-772
25
Steichen O,
Zinzindohoué F,
Plouin PF,
Amar L.
Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review. Horm Metab Res 2012; 44: 221-227